user avatar
C. Ola Landgren, M.D.
@DrOlaLandgren
Professor of Medicine, Chief of Myeloma Division & Translational Clinical Oncology Program. Sylvester Comprehensive Cancer Center, Univ of Miami. Tweets = mine
Miami, FL
umiamihealth.org/en/sylvester-c…
Joined January 2014
85
Following
11.7K
Followers
Posts
  • user avatar
    C. Ola Landgren, M.D.
    @DrOlaLandgren
    Aug 10, 2020
    Excited to join ⁦@SylvesterCancer⁩ & ⁦@univmiami⁩ in Miami on Nov 1, 2020 as inaugural Leader of Experimental Therapeutics Program & Leader of Myeloma Program! Forever grateful to ⁦@sloan_kettering⁩ for fantastic 6+ yrs #mmsm ⁦@theMMRF⁩ ⁦@IMFmyeloma⁩
  • user avatar
    C. Ola Landgren, M.D.
    @DrOlaLandgren
    Dec 7, 2022
    YAY!!! Sylvester Comprehensive Cancer Center has received approval to build world-class MYELOMA RESEARCH INSTITUTE in Miami! Truly outstanding for myeloma patients! #mmsm @IMFmyeloma @theMMRF @HealthTreeMM @SylvesterCancer #ASH22 @DrSDNimer @AnnKeilDux physician-news.umiamihealth.org/sylvester-rece…
  • user avatar
    C. Ola Landgren, M.D.
    @DrOlaLandgren
    Apr 15, 2021
    JAMA Oncology: Our KRd-daratumumab clinical trial for newly diagnosed multiple myeloma patients online today (MANHATTAN trial), showing 71% MRD negativity in the absence of bone marrow transplant. Unprecedented results! #mmsm @SylvesterCancer @theMMRF @IMFmyeloma @sloan_kettering
    user avatar
    JAMA Oncology
    @JAMAOnc
    Apr 15, 2021
    Modern 4-drug combination therapy (carfilzomib-lenalidomide-dexamethasone-daratumumab) is safe, well-tolerated & offers high rates of MRD negativity by itself (ie, in the absence of autologous transplant) in pts w/newly diagnosed multiple myeloma ja.ma/3uXLImx #MMSM
  • user avatar
    C. Ola Landgren, M.D.
    @DrOlaLandgren
    May 1, 2020
    Outstanding news today for myeloma patients: FDA approves subcutaneous Daratumumab, DARZALEX FASPRO (daratumumab & hyaluronidase-fihj). Fixed-dose injection given in 3 to 5 minutes. Convenient, safe, effective! #mmsm ⁦@theMMRF⁩ ⁦@IMFmyeloma⁩
    globenewswire.com
    Genmab Announces U.S. FDA Approval of Subcutaneous Formulation of Daratumumab, DARZALEX FASPRO™...
    Company Announcement Subcutaneous formulation of daratumumab, DARZALEX FASPRO™, approved by the U.S. FDA for the treatment of patients with multiple...
  • user avatar
    C. Ola Landgren, M.D.
    @DrOlaLandgren
    Aug 14, 2023
    BREAKING NEWS: Today, FDA approved another bispecific BCMAxCD3-targeted monoclonal antibody "Elranatamab" for relapsed/refractory myeloma! Great for patients! #mmsm @IMFmyeloma @theMMRF @HealthtreeMM @ASH_hematology @SylvesterCancer onclive.com/view/fda-appro… via @onclive
    FDA Approves Elranatamab for Relapsed or Refractory Multiple Myeloma | OncLive
    onclive.com
    FDA Approves Elranatamab for Relapsed or Refractory Multiple Myeloma | OncLive
    The FDA has granted accelerated approval to elranatamab-bcmm (Elrexfio) for the treatment of adult patients with relapsed or refractory multiple myeloma who have previously received at least 4 lines...
    18K
  • user avatar
    C. Ola Landgren, M.D.
    @DrOlaLandgren
    Sep 4, 2021
    Myeloma is the 2nd most common hematological malignancy globally affecting 450 579 individuals in 2020. We are about to enter a new era with amazing immunotherapies. Great for patients! ⁦@TheLancet⁩ ⁦⁦@dikokaz⁩ #mmsm ⁦@SylvesterCancer⁩ thelancet.com/journals/lance…
  • user avatar
    C. Ola Landgren, M.D.
    @DrOlaLandgren
    Apr 13, 2024
    Great victory in myeloma today: ODAC voted 12-0 for MRD as early endpoint for accelerated approval in myeloma Honored to present EVIDENCE meta-analysis, work I pioneered 15 yrs ago. Congrats also to I2TEAMM ⁦@IMFmyeloma⁩ ⁦@theMMRF⁩ #mmsm ⁦@HealthTree⁩ #myeloma
    11K
  • user avatar
    C. Ola Landgren, M.D.
    @DrOlaLandgren
    Jan 11, 2021
    Today, we open our new “Myeloma Genomic Laboratory” at Sylvester Comprehensive Cancer Center, Univ of Miami! Lots of exciting research in pipeline! ⁦@FrancescoMaura4⁩ ⁦@BachisioZic⁩ @arjun50695688 ⁦@SylvesterCancer⁩ #mmsm ⁦@theMMRF⁩ umiamihealth.org/en/sylvester-c…
  • user avatar
    C. Ola Landgren, M.D.
    @DrOlaLandgren
    Dec 29, 2021
    Cancer Surfaceome Atlas: integrates genomic, functional and drug response data to identify actionable targets. Comprehensive, pan-cancer, identification and annotation of genes encoding cell-surface proteins. #mmsm ⁦@NatureCancer⁩ nature.com/articles/s4301…
  • user avatar
    C. Ola Landgren, M.D.
    @DrOlaLandgren
    Dec 11, 2022
    When at ASH, Vincent and I always meet for a long lunch to discuss meaning of life & non-work things. Friendship & scientific collaboration for almost 20 years. Thank you! @VincentRK⁩ ⁦@theMMRF⁩ ⁦@IMFmyeloma⁩ ⁦@HealthTreeMM⁩ #ASH22 ⁦@MayoClinic⁩
  • user avatar
    C. Ola Landgren, M.D.
    @DrOlaLandgren
    Dec 8, 2021
    I have decided to change my plans and cancel my in-person attendance at #ASH21 due recent developments with #COVID19 . I will attend the meeting virtually. I look forward to an in-person attendance at #ASH22 . #mmsm @IMFmyeloma @theMMRF @LLSusa @SylvesterCancer
  • user avatar
    C. Ola Landgren, M.D.
    @DrOlaLandgren
    May 29, 2021
    Very impressive results: Cilta-cel BCMA targeted CAR-T cell therapy for relapsed/refractory multiple myeloma shows 22.8 months median time free of progression - and off all therapy! Great for patients! #ASCO21 @JanssenOncUS #mmsm businesswire.com/news/home/2021…
  • user avatar
    C. Ola Landgren, M.D.
    @DrOlaLandgren
    Oct 12, 2021
    "Congrats, MRD negative after completed multiple myeloma combination therapy!" My patient was out fishing north of Miami during telemedicine clinic visit. Modern medicine! @SylvesterCancer #mmsm @theMMRF @IMFmyeloma @myelomacrowd @dikokaz @Denny19 @Drjhoffmanmiami @BenDiamondMD
  • user avatar
    C. Ola Landgren, M.D.
    @DrOlaLandgren
    Dec 2, 2018
    Poster #3281 is up: modem 4-drug daratumumab-KRd combination for newly diagnosed myeloma. Bone marrow & blood-based MRD. Targeting up to 80% MRD negativity without transplant. Early results with potential to be transformative #ASH18 @sloan_kettering #mmsm @theMMRF @IMFmyeloma